📊 DCOY Key Takeaways
Investment Thesis
Decoy Therapeutics is a pre-revenue pharmaceutical company with zero sales and significant operating losses (-$3.6M), indicating the company is in early clinical/development stages with no commercialized products. Despite adequate near-term liquidity (4.8M cash, 5.85x current ratio), the -$3.7M operating cash burn rate provides only ~15 months of runway, creating critical solvency risk. The deteriorating EPS (-$14.35) and negative ROE/ROA signal unsustainable financial performance with no clear path to profitability without substantial capital raises or successful drug commercialization.
DCOY Strengths
- Strong immediate liquidity position with $4.8M in cash and 5.85x current ratio
- Zero debt/leverage provides financial flexibility for future capital raises
- Minimal capital expenditure requirements suggest asset-light operational model
DCOY Risks
- Zero revenue with no near-term commercialization catalysts visible in fundamentals
- Monthly burn rate of ~$310K implies only 15 months of cash runway remaining
- Pre-revenue biotech model subject to extreme execution risk and clinical trial failure probability
- Negative returns on equity (-83.4%) and assets (-58.1%) indicate value destruction
- Single Form 4 insider filing in 90 days suggests limited insider confidence/activity
Key Metrics to Watch
- Quarterly operating cash burn rate and cash runway months
- Clinical trial progress updates and regulatory pathway milestones
- Capital raise announcements and dilution impact on equity holders
- Achievement of revenue-generating milestones or partnership agreements
DCOY Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.85x current ratio provides a solid financial cushion.
DCOY Profitability Ratios
DCOY vs Healthcare Sector
How Decoy Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
DCOY Balance Sheet & Liquidity
DCOY 5-Year Financial Trend
5-Year Trend Summary: Decoy Therapeutics Inc.'s revenue has grown significantly by 44% over the 5-year period, indicating strong business expansion. The most recent EPS of $-30.74 indicates the company is currently unprofitable.
DCOY Growth Metrics (YoY)
DCOY Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2023 | N/A | -$5.3M | $-2.23 |
| Q3 2022 | N/A | -$1.9M | $-2.09 |
| Q2 2022 | N/A | -$1.9M | $-0.07 |
| Q1 2022 | N/A | -$1.9M | $-0.06 |
| Q3 2021 | N/A | -$1.7M | $-0.08 |
| Q2 2021 | $571.4K | -$1.8M | $-0.07 |
| Q1 2021 | $1.1M | -$1.9M | N/A |
| Q3 2020 | $874.9K | -$903.6K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DCOY Capital Allocation
DCOY SEC Filings
Access official SEC EDGAR filings for Decoy Therapeutics Inc. (CIK: 0001615219)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DCOY
What is the AI rating for DCOY?
Decoy Therapeutics Inc. (DCOY) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are DCOY's key strengths?
Claude: Strong immediate liquidity position with $4.8M in cash and 5.85x current ratio. Zero debt/leverage provides financial flexibility for future capital raises.
What are the risks of investing in DCOY?
Claude: Zero revenue with no near-term commercialization catalysts visible in fundamentals. Monthly burn rate of ~$310K implies only 15 months of cash runway remaining.
What is DCOY's revenue and growth?
Decoy Therapeutics Inc. reported revenue of $0.0.
Does DCOY pay dividends?
Decoy Therapeutics Inc. does not currently pay dividends.
Where can I find DCOY SEC filings?
Official SEC filings for Decoy Therapeutics Inc. (CIK: 0001615219) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DCOY's EPS?
Decoy Therapeutics Inc. has a diluted EPS of $-14.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.